REGENOVUE

Product Overview

REGENOVUE is a South Korean hyaluronic acid (HA) dermal filler range developed by NeoGenesis Co., Ltd. The portfolio includes six formulations: REGENOVUE FINE, DEEP, SUB-Q, FINE PLUS, DEEP PLUS, and SUB-Q PLUS. All six contain 24 mg/mL cross-linked hyaluronic acid, while the three PLUS formulations additionally contain 0.3% lidocaine (3 mg/mL). The range offers different gel characteristics for professional facial wrinkle correction, soft-tissue volume restoration, and facial contouring.

REGENOVUE is manufactured using non-animal-derived hyaluronic acid and BDDE cross-linking technology. The manufacturer describes its fillers as homogeneous, monophasic HA gels designed to provide consistent material characteristics and controlled extrusion.

The product family is organized into three primary gel categories. FINE is the softer formulation, commercially positioned for superficial wrinkles and fine lines. DEEP provides intermediate structural support for more pronounced facial wrinkles and folds. SUB-Q is the most volume-oriented formulation, designed for deeper soft-tissue correction and facial contour enhancement.

Each category is available with or without lidocaine. Standard REGENOVUE formulations contain cross-linked HA without added lidocaine, while PLUS formulations incorporate 3 mg/mL lidocaine to help reduce discomfort associated with professional administration.

The manufacturer documents 1.0 mL and 1.1 mL syringe presentations, depending on the product configuration and market. Each commercial package contains one sterile pre-filled syringe with disposable needles selected according to the filler grade.

This TEOSQUARE product page provides a comprehensive overview of all six REGENOVUE formulations, including their ingredients, gel characteristics, differences between lidocaine and non-lidocaine versions, packaging specifications, storage requirements, and safety considerations.

Key Features

• 24 mg/mL Cross-Linked Hyaluronic Acid: All six formulations contain 24 mg/mL HA, providing a consistent hyaluronic acid concentration across the product family.
• Six Product Variants: Available in FINE, DEEP, SUB-Q, FINE PLUS, DEEP PLUS, and SUB-Q PLUS formulations.
• Lidocaine and Non-Lidocaine Options: Standard formulations contain no added lidocaine, while PLUS formulations contain 0.3% lidocaine (3 mg/mL).
• Three Gel Characteristics: FINE, DEEP, and SUB-Q provide different degrees of viscoelasticity and structural support for distinct facial correction requirements.
• Homogeneous Monophasic Structure: NeoGenesis describes REGENOVUE as a densely cross-linked HA gel with a uniform internal structure.
• Non-Animal-Derived HA: Uses hyaluronic acid obtained through bacterial fermentation rather than extraction from animal tissues.
• BDDE Cross-Linking: Uses a controlled cross-linking process to stabilize the HA gel, followed by purification to reduce residual manufacturing-related substances.
• Ultra-Thin-Wall Needles: Manufacturer-documented packaging includes disposable needles with specifications selected according to the filler grade.
• South Korean Product: Developed within the NeoGenesis product portfolio and supplied internationally for professional medical aesthetic use.

Composition & Specifications

The principal ingredient in REGENOVUE is cross-linked sodium hyaluronate, commonly described as cross-linked hyaluronic acid.

All six formulations contain 24 mg/mL HA. The three PLUS formulations additionally contain lidocaine hydrochloride at 3 mg/mL, equivalent to 0.3%.

The manufacturer's technical documentation also identifies phosphate-buffered saline and related buffering ingredients as supporting formulation components.

Cross-Linked Hyaluronic Acid — 24 mg/mL

Hyaluronic acid is a naturally occurring glycosaminoglycan found in the extracellular matrix of connective tissues, including the skin.

It is highly hydrophilic and contributes to tissue hydration, viscoelasticity, and the structural characteristics of the extracellular matrix.

REGENOVUE contains 24 mg/mL cross-linked HA in every FINE, DEEP, and SUB-Q formulation, regardless of lidocaine content.

The manufacturer identifies sodium hyaluronate as the principal ingredient and uses a cross-linking process to form a stabilized gel network.

Cross-linking creates chemical connections between HA polymer chains, increasing their resistance to degradation compared with non-crosslinked hyaluronic acid.

This stabilized gel structure allows HA to provide temporary physical volume within soft tissue.

The physical behavior of each REGENOVUE grade depends on additional properties, including its cross-linking characteristics, elasticity, viscosity, and cohesivity.

Therefore, identical HA concentrations do not mean that FINE, DEEP, and SUB-Q have identical mechanical properties or clinical applications.

Lidocaine — 0.3% in PLUS Formulations

Lidocaine is an amide-type local anesthetic commonly incorporated into injectable dermal fillers.

It temporarily inhibits sensory nerve conduction by blocking voltage-gated sodium channels in nerve cell membranes.

This mechanism reduces the propagation of electrical signals associated with pain.

REGENOVUE FINE PLUS, DEEP PLUS, and SUB-Q PLUS each contain 3 mg/mL lidocaine hydrochloride, equivalent to 0.3%.

Lidocaine is included to help reduce discomfort associated with professional filler administration.

The standard FINE, DEEP, and SUB-Q formulations do not contain added lidocaine.

The PLUS designation identifies the presence of lidocaine. It does not indicate a higher HA concentration or automatically establish greater filling capacity.

BDDE Cross-Linking Agent

BDDE, or 1,4-butanediol diglycidyl ether, is a chemical cross-linking agent used in manufacturing certain stabilized hyaluronic acid fillers.

During manufacturing, BDDE forms connections between HA polymer chains, contributing to the gel's mechanical and degradation characteristics.

NeoGenesis describes a manufacturing process designed to achieve a dense cross-linked structure while limiting the quantity of cross-linking agent required.

The manufacturer's technical documentation specifies a residual BDDE limit of no more than 2 ppm and describes purification testing in which residual BDDE was not detected.

A reported nondetect result does not mean that the finished product is chemically free of every cross-linking-related residue.

BDDE is a manufacturing-related component rather than an intended therapeutic active ingredient.

Phosphate-Buffered Saline

REGENOVUE uses phosphate-buffered saline as part of its supporting formulation.

The manufacturer's technical specifications identify sodium chloride and phosphate salts as components contributing to the physicochemical properties of the gel.

These ingredients help maintain appropriate formulation conditions and should be distinguished from the principal HA filler material and the lidocaine anesthetic component.

The principal differentiating ingredients are cross-linked HA at 24 mg/mL and, in PLUS formulations only, lidocaine at 0.3%. Supporting excipient specifications should be verified against the original product labeling for the selected model.

Available REGENOVUE Variants

REGENOVUE consists of six formulations organized into three gel categories, each available with or without lidocaine.

FINE, DEEP, and SUB-Q differ primarily in their physical gel characteristics and intended commercial applications. The corresponding PLUS formulations contain the same declared HA concentration with the addition of 0.3% lidocaine.

REGENOVUE FINE

REGENOVUE FINE is the softer, non-lidocaine formulation within the product family.

It contains 24 mg/mL cross-linked hyaluronic acid without added lidocaine.

FINE is commercially positioned for temporary correction of superficial wrinkles and fine facial lines.

The manufacturer's product materials associate this grade with areas where relatively subtle tissue correction is required, including fine lines around the eyes and mouth.

The formulation is supplied in a sterile pre-filled syringe with a documented needle configuration consisting of one 30G needle and one 27G needle.

REGENOVUE DEEP

REGENOVUE DEEP is the intermediate non-lidocaine formulation.

It contains 24 mg/mL cross-linked hyaluronic acid without added lidocaine.

DEEP is positioned for temporary correction of moderate to deep facial wrinkles and folds.

Compared with FINE, the formulation is intended to provide greater structural support for more pronounced soft-tissue correction.

Commercial applications include selected facial folds and contour-related concerns, subject to the approved indications of the destination market.

Its documented package includes one pre-filled syringe and two 27G needles.

REGENOVUE SUB-Q

REGENOVUE SUB-Q is the volume-oriented non-lidocaine formulation within the REGENOVUE facial filler range.

It contains 24 mg/mL cross-linked hyaluronic acid without added lidocaine.

SUB-Q features gel characteristics intended to provide relatively greater resistance to deformation and physical support.

It is commercially positioned for facial volume restoration, deep wrinkle correction, and selected contouring applications.

The manufacturer's product materials distinguish SUB-Q from FINE and DEEP through its more volume-oriented material characteristics.

Its documented packaging includes one pre-filled syringe, one 27G needle, and one 25G needle.

REGENOVUE FINE PLUS

REGENOVUE FINE PLUS is the lidocaine-containing counterpart of REGENOVUE FINE.

Each formulation contains 24 mg/mL cross-linked HA, while FINE PLUS additionally contains 0.3% lidocaine (3 mg/mL).

It maintains the softer gel positioning associated with the FINE category.

FINE PLUS is commercially designed for temporary correction of superficial wrinkles and fine lines, with lidocaine included to help reduce procedural discomfort.

The documented package includes one pre-filled syringe, one 30G needle, and one 27G needle.

REGENOVUE DEEP PLUS

REGENOVUE DEEP PLUS combines 24 mg/mL cross-linked HA with 0.3% lidocaine.

It is the lidocaine-containing counterpart of REGENOVUE DEEP.

DEEP PLUS provides intermediate gel characteristics and is commercially positioned for correction of moderate to deep facial wrinkles and folds.

The lidocaine component is intended to help reduce discomfort associated with professional administration.

The standard documented package includes one pre-filled syringe and two 27G needles.

REGENOVUE SUB-Q PLUS

REGENOVUE SUB-Q PLUS is the lidocaine-containing version of the volume-oriented SUB-Q filler.

It contains 24 mg/mL cross-linked hyaluronic acid and 0.3% lidocaine.

SUB-Q PLUS is positioned for pronounced facial volume deficits and contour correction requiring a relatively supportive HA gel.

NeoGenesis describes SUB-Q formulations as having strong viscoelastic characteristics within the product family.

The manufacturer's technical materials include rheological testing of the lidocaine-containing SUB-Q formulation.

Its documented package contains one pre-filled syringe, one 27G needle, and one 25G needle.

All six products contain the same declared HA concentration. The FINE, DEEP, and SUB-Q categories differ in gel characteristics, while PLUS identifies the addition of 0.3% lidocaine. Product selection and anatomical use must follow the applicable instructions for use.

How REGENOVUE Hyaluronic Acid Fillers Work

REGENOVUE fillers provide temporary physical soft-tissue restoration through the properties of cross-linked hyaluronic acid.

Their effects are based primarily on the hydrated gel's ability to occupy space within soft tissue and maintain a degree of structural support.

Physical Volume Restoration

Cross-linked HA forms a stabilized, hydrated gel capable of temporarily replacing or supplementing soft-tissue volume.

When used within an authorized indication, this property can improve the appearance of selected wrinkles, folds, and volume deficits.

FINE, DEEP, and SUB-Q differ in their intended level of physical correction and structural support.

Hyaluronic Acid and Hydration

Hyaluronic acid interacts strongly with water through its hydrophilic molecular structure.

This property contributes to the hydration and viscoelastic characteristics of HA-based gels.

REGENOVUE combines these properties with chemical cross-linking to produce a stabilized dermal filler.

Gel Viscoelasticity

Viscoelasticity describes how a material responds to mechanical forces through a combination of elastic and viscous behavior.

Elasticity contributes to resistance against deformation, while viscosity describes resistance to flow.

These properties influence the physical behavior of dermal fillers within soft tissue.

The REGENOVUE range uses different gel characteristics to distinguish relatively soft wrinkle-correction formulations from more supportive facial volumizing formulations.

Temporary Biodegradation

Hyaluronic acid is biodegradable and gradually undergoes enzymatic and non-enzymatic breakdown.

Chemical cross-linking generally increases the gel's resistance to degradation compared with non-crosslinked HA.

The persistence of the filler depends on its formulation, tissue environment, and individual physiological factors.

Local Anesthetic Action in PLUS Formulations

REGENOVUE PLUS formulations contain lidocaine, which temporarily inhibits sensory nerve signaling through voltage-gated sodium channel blockade.

This additional ingredient is intended to help reduce discomfort during professional administration.

Lidocaine does not change the fundamental physical filling mechanism of the hyaluronic acid gel.

These mechanisms describe established hyaluronic acid and lidocaine properties. They do not guarantee a specific treatment duration, degree of volume restoration, or absence of complications.

Cross-Linking Technology & Gel Characteristics

NeoGenesis describes REGENOVUE as a monophasic cross-linked hyaluronic acid filler developed using proprietary manufacturing and purification processes.

Homogeneous Monophasic Gel

Monophasic HA fillers are characterized by a relatively homogeneous gel structure.

REGENOVUE's manufacturer emphasizes a uniform, densely cross-linked structure intended to provide consistent material behavior.

These characteristics are associated with the gel's cohesivity, physical support, and extrusion properties.

A monophasic structure does not independently establish superior clinical outcomes compared with other filler technologies.

Controlled BDDE Cross-Linking

NeoGenesis uses BDDE to create chemical connections between hyaluronic acid polymer chains.

Its technical documentation describes a manufacturing approach intended to achieve desired gel characteristics while controlling the degree of chemical modification.

The manufacturer reports different degrees of modification for its FINE PLUS, DEEP PLUS, and SUB-Q PLUS formulations, reflecting differences in their cross-linking characteristics.

Degree of modification is not identical to the concentration of residual free BDDE.

Purification and Residual BDDE

Residual cross-linking agent is an important manufacturing quality-control consideration for chemically cross-linked HA fillers.

NeoGenesis describes purification methods intended to reduce residual BDDE and other process-related substances.

The manufacturer's technical specification identifies a residual BDDE limit of 2 ppm or less.

However, a product's residual BDDE specification does not independently establish that it is free from inflammation, hypersensitivity, or other complications.

Extrusion Characteristics

Extrusion force describes the force required to move a filler through a syringe and needle under specified test conditions.

NeoGenesis has published laboratory testing describing the extrusion characteristics of REGENOVUE FINE, DEEP, and SUB-Q.

The company associates its homogeneous gel structure with relatively consistent extrusion behavior.

The manufacturer also supplies ultra-thin-wall needles, which provide a larger internal diameter than certain conventional needles of the same external gauge.

These material and accessory characteristics may influence handling but do not establish a painless procedure or eliminate injection-related risks.

Manufacturing technology, cross-linking characteristics, and laboratory rheology measurements provide information about material properties. Clinical performance and safety must be evaluated using appropriate finished-product evidence.

Packaging & Product Presentation

REGENOVUE fillers are supplied as sterile, pre-filled hyaluronic acid gel syringes.

NeoGenesis documents both 1.0 mL and 1.1 mL syringe presentations. Individual commercial listings may specify only one of these volumes.

Each manufacturer-documented box contains one syringe and two disposable needles. Needle specifications differ between FINE, DEEP, and SUB-Q.

1.0 mL and 1.1 mL Syringe Presentations

The manufacturer's catalogue lists 1.0 mL and 1.1 mL as documented syringe-volume options.

Both presentations maintain the declared 24 mg/mL HA concentration.

The PLUS versions additionally maintain the declared 3 mg/mL lidocaine concentration.

Because syringe volume may differ by market and product configuration, buyers should verify the exact net volume printed on the original packaging.

Disposable Needles

NeoGenesis provides different disposable needle configurations according to the REGENOVUE gel category.

The manufacturer's catalogue identifies ultra-thin-wall needles as part of the commercial presentation.

The documented needle specifications are provided for packaging identification and should not be interpreted as instructions for anatomical placement or injection technique.

Original Product Identification

Buyers should verify the original product name, lidocaine designation, syringe volume, needle configuration, batch number, expiration date, and legal manufacturer information.

The original package and instructions for use should be checked to confirm that the supplied presentation corresponds to the intended product registration.

The manufacturer documents 1.0 mL and 1.1 mL presentations. These are alternative commercial syringe specifications, not two separate concentrations or treatment strengths.

Storage & Handling

NeoGenesis specifies storage between 2°C and 25°C for the REGENOVUE FINE, DEEP, and SUB-Q product families, including their PLUS counterparts.

The manufacturer identifies a shelf life of 24 months for the documented formulations.

• Storage Temperature: Store at 2°C to 25°C according to the manufacturer's product specifications.
• Freezing Protection: Do not freeze the product.
• Light Protection: Protect from direct sunlight and excessive environmental exposure.
• Original Packaging: Keep the syringe in its original manufacturer packaging until required for authorized professional use.
• Sterile Barrier Integrity: Do not use products with damaged packaging or evidence of compromised sterility.
• Single-Use Handling: Follow the manufacturer's requirements for single-patient use and disposal.
• Product Traceability: Verify the exact formulation, lot number, expiration date, manufacturer, and applicable regulatory labeling.

Shelf Life

The manufacturer documents a shelf life of 24 months for the REGENOVUE filler series.

The expiration date printed on the supplied product takes precedence over general catalogue specifications.

Storage and shelf-life information should be verified against the original instructions for use for the exact supplied formulation and destination market.

Safety & Regulatory Considerations

REGENOVUE products are injectable hyaluronic acid medical devices intended for use by appropriately qualified healthcare professionals.

Professional use requires consideration of patient-specific conditions, anatomical characteristics, product properties, contraindications, and the risks associated with injectable dermal fillers.

Potential Adverse Reactions

Potential adverse reactions associated with injectable HA fillers include localized pain, redness, swelling, bruising, tenderness, itching, and temporary inflammation.

Other possible complications include infection, hypersensitivity reactions, delayed inflammation, persistent nodules, granulomatous reactions, and product migration.

The frequency and severity of complications depend on the finished formulation, patient characteristics, and circumstances of administration.

Vascular Complications

Accidental introduction of dermal filler into a blood vessel can obstruct blood flow and cause serious tissue injury.

Potential complications include vascular occlusion, tissue ischemia, necrosis, visual impairment, blindness, and stroke.

These risks are not eliminated by a homogeneous gel structure, controlled cross-linking, high HA purity, or the presence of lidocaine.

Lidocaine-Related Precautions

REGENOVUE FINE PLUS, DEEP PLUS, and SUB-Q PLUS contain 0.3% lidocaine.

Individuals with known hypersensitivity to lidocaine, other amide-type local anesthetics, or relevant formulation components may have contraindications to the lidocaine-containing products.

The non-lidocaine formulations do not contain added lidocaine but remain subject to the general risks associated with injectable HA fillers.

Hyaluronic Acid Biodegradation

Hyaluronic acid is biodegradable, and hyaluronidase may be used under appropriate medical circumstances to degrade HA fillers.

However, the potential use of hyaluronidase does not guarantee complete reversal of every complication or prevention of permanent tissue injury.

Clinical Performance Claims

NeoGenesis describes expected aesthetic effects lasting approximately 8–12 months for the FINE category and 12–18 months for DEEP and SUB-Q.

These values are manufacturer-reported expectations rather than guaranteed clinical durations.

Results vary according to formulation properties, the treatment area, individual patient characteristics, and other clinical factors.

Laboratory comparisons of gel elasticity, viscosity, or extrusion force should not independently be interpreted as evidence of superior clinical safety or longer-lasting results.

Manufacturer and Product Identification

REGENOVUE is developed and commercially represented by NeoGenesis Co., Ltd. in South Korea.

Historical European regulatory documentation dated 2018 also identifies JETEMA Co., Ltd. as the legal manufacturer for certain REGENOVUE FINE, DEEP, and SUB-Q products.

Therefore, the current responsible legal manufacturer should be verified from the original labeling and regulatory documentation for the specific supplied model and market.

International Regulatory Authorization

NeoGenesis's product catalogue describes CE certification for the REGENOVUE filler series, including lidocaine-containing formulations.

Historical European conformity documentation exists for selected REGENOVUE products under the former European Medical Devices Directive.

However, historical certification does not independently establish current authorization under the European Medical Device Regulation for every product or destination market.

US FDA approval for the six REGENOVUE formulations described on this page has not been established.

Regulatory approval of another hyaluronic acid filler does not automatically extend to REGENOVUE.

Professional buyers should verify the current model-specific authorization, legal manufacturer, approved indications, import eligibility, and distribution requirements applicable to their destination country.

This information is intended for professional product identification and commercial evaluation. It does not provide injection instructions, establish patient-specific suitability, or authorize use outside applicable medical device regulations. Clinical use must follow the current manufacturer-issued instructions for use.

Frequently Asked Questions